Financials
| Half-year Report | May. 02, 2025 |
| Posting of Annual Report and Notice of AGM | Feb. 14, 2025 |
| Annual Results for period ended 30 September 2024 | Jan. 29, 2025 |
| Half-year Report | Jun. 18, 2024 |
| Results for the period ended 30 September 2023 | Jan. 03, 2024 |
| Unaudited Interim Report | May. 22, 2023 |
| Half-year Report | Dec. 13, 2022 |
Proxies
| Result of AGM | Mar. 20, 2025 |
| Result of AGM | Mar. 19, 2024 |
| Posting of Annual Report and Notice of AGM | Jan. 15, 2024 |
| Result of Annual General Meeting | Aug. 24, 2023 |
| Notice of AGM | Jul. 31, 2023 |
| Result of AGM | Aug. 25, 2022 |
| Posting of Annual Report and Notice of AGM | Aug. 01, 2022 |
Ownership Update
| Director/PDMR Dealings | Nov. 05, 2024 |
| Holding(s) in Company | Jul. 26, 2023 |
| Holding(s) in Company | Apr. 26, 2023 |
| Holding(s) in Company | Jan. 03, 2023 |
| Holding(s) in Company | Nov. 16, 2022 |
| Holding(s) in Company | Aug. 19, 2022 |
| Holding(s) in Company | Jun. 20, 2022 |
Announcements
| Total Voting Rights | May. 30, 2025 |
| Confirmation of European ODD for NXP002 | May. 29, 2025 |
| Publication of a Prospectus | May. 23, 2025 |
| £210,000 Placing | May. 22, 2025 |
| Attendance at American Thoracic Society Congress | May. 19, 2025 |
| Confirmation of European Orphan Drug Designation | Apr. 30, 2025 |
| Change of Registered Office and Company Secretary | Apr. 29, 2025 |
Prospectuses
| Prospectus | May. 23, 2025 |
| Prospectus re: Proposed Acquisition of Nuformix | Sep. 15, 2017 |